Shots:

• The P-IIa POC OSCAR study involves assessing the efficacy and safety of otilimab (90mg- IV) + SOC vs PBO + SOC in 806 hospitalized adults with aged 18-79yrs. with severe COVID-19 related pulmonary disease
• The study showed a 5.3% overall treatment difference in all age patients but did not reach statistically significant. The pre-planned efficacy analysis in the 70-plus cohort showed patients were alive and free of respiratory failure @28days (65.1% vs 45.9%)
• The mortality analysis up to day60; 14.4% treatment difference favoring otilimab with rates of 40.4% for those who received SOC only vs 26% on otilimab plus SOC in patients aged≥17yrs.

 ­ Ref: GSK | Image: GSK